An antibody therapy against a key inflammatory molecule involved in migraines reduces the number of headaches that chronic migraine patients experience per month in a phase III trial
A new study of fremanezumab, an immunotherapy that counteracts one of the molecules released during migraine, was found successful in reducing the number of days that chronic migraine sufferers experienced headaches. The results of the phase III clinical trial were published November 29, 2017 in the New England Journal of Medicine.
The World Health Organization estimates that between 127 and 300 million people around the world experience chronic migraine, defined as 15 or more headaches per month for at least three months. The disease can be debilitating and although a number of interventions exist, many only work for a certain time before they fail to prevent or relieve pain.
“This therapeutic approach offers new hope for people whose migraines cannot be treated with existing medicine,” says Stephen D. Silberstein, M.D., principal investigator of the HALO CM trial, Professor of Neurology and Director of the Jefferson Headache Center at the Vicki & Jack Farber Institute for Neuroscience at Thomas Jefferson University Hospital. “Our worldwide effort to evaluate this novel therapeutic approach has shown positive results and was safe in patients.”
Fremanezumab, a monocolonal antibody developed by Teva Pharmaceuticals, is a biological agent that binds to and blocks the action of a migraine-associated protein called calcitonin gene-related peptide (CGRP). Mounting evidence of its importance in migraines has made CGRP a focal point of research and drug development. The peptide is released at high levels during migraine in response to inflammation, and triggers a cascade effect that stimulates more CGRP release. This results in increasing sensitivity of the brain to pain. By blocking this peptide, doctors hope to break the cycle of increasing inflammation and increased pain sensitivity that contributes to migraine headaches.
Researchers from 132 sites across nine countries enrolled 1130 patients and randomly assigned them to one of three groups: one that received quarterly treatments, a group that received one treatment per month, and one that received placebo injections. The trial lasted for 16 weeks, with a 12-week treatment window.
The results of the trial show that treatment with fremanezumab reduced the number of days patients experience headache by an average of 4.3 days with quarterly treatment and 4.6 days with monthly treatment. “We saw some patients with 100 percent reduction in migraine, others with 75 percent reduction,” says Dr. Silberstein. The level of response varied between patients.
The researchers also looked at how well the therapy worked relative to each patient’s headache burden. They calculated the percent of patients who had more than a 50 percent reduction in the number of days they experienced either a severe or moderate headache per month. Using this measure, the researchers saw that 37.6 percent of patients on the monthly regimen, and 40.8 percent on the quarterly regimen had at least a 50 percent reduction in the number of moderate headaches per month, compared to 18.1 percent in the placebo group.
The therapy had a favorable safety profile with the most common adverse event reported as irritation at injection site, which was reported in the placebo group as well.
“If approved, this treatment would provide physicians with an important new tool to help prevent migraine, reduce a patient’s migraine load, and potentially help patients return to normal” says Dr. Silberstein.
The Latest on: Migraines
[google_news title=”” keyword=”migraines” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
- Study links common headaches to neck inflammationon December 2, 2023 at 12:16 pm
London, Dec 2 (IANS) Researchers have identified objective evidence of how the neck muscles are involved in primary headaches, such as tension-type headaches and migraines, according to a study.
- Does COVID-19 Vaccination Worsen Migraines?on December 2, 2023 at 5:06 am
New research says no. A recent study published in the European Journal of Neurology has shown that both COVID-19 and its vaccinations have minimal impact on migraine severity. This conclusion was draw ...
- Concussions kept Scott Ramsay from bigger hockey prospects. His PhD work will help kids today get better careon December 1, 2023 at 11:00 pm
The former professional hockey player launched a study of 23,000 children and youth in B.C. who had been identified with concussions, focusing on their experiences in the province’s health care system ...
- When two major illnesses collide for one patienton November 30, 2023 at 4:00 pm
For decades, Tanya Di Raddo thought she was suffering from severe migraines. But by her mid 40s she was diagnosed with two illnesses at the same time. She turned to The Ottawa Hospital’s MS Clinic and ...
- Cause of migraines and headaches FINALLY revealed as experts make bombshell breakthroughon November 30, 2023 at 6:26 am
While tension headaches and migraines are the most common type of head pain, their true cause has been unknown - until now ...
- What causes common headaches and migraines? Experts think they finally knowon November 29, 2023 at 2:39 pm
Tension headaches and migraines are the most common types of head pains, yet the exact source of those conditions has alluded health professionals — until now.
- Dentists: This Simple Jaw Massage May Ward Off Tension Headaches and Migraineson November 29, 2023 at 7:29 am
Moist heat helps loosen up your masseter muscles so they stretch more easily. Place the compress (a warm, damp washcloth will do the trick) to the area right in front of your ear and hold it there for ...
- Neck inflammation revealed as the hidden cause of many common headacheson November 28, 2023 at 4:00 pm
Primary headaches, like tension-type headaches and migraines, affect millions worldwide, yet their exact causes remain elusive. Tension-type headaches, experienced by two-thirds of U.S. adults, are ...
- CBD May Relieve the Pain of Migraineson November 27, 2023 at 4:00 pm
Migraine is common, and one of the most disabling painful conditions. Migraines are initiated by a large variety of triggers that ultimately activate the trigeminal system of nerves that project ...
- 7 images show what people see when they get debilitating migraines with aura, from flashing lights to geometric shapeson November 24, 2023 at 8:59 am
"There are multiple different types of visual aura sufferers experience. But they can usually be categorized in seven ways: flashes of light, zig-zags, blind spots, tunnel vision, geometric shapes, ...
via Google News and Bing News